Bulletin of Experimental Biology and Medicine

, Volume 162, Issue 4, pp 552–557 | Cite as

Effect of Fibroblast-Like Cells of Mesenchymal Origin of Cytotoxic Activity of Lymphocytes against NK-Sensitive Target Cells

  • A. Yu. Lupatov
  • Ya. S. Kim
  • O. A. Bystrykh
  • I. V. Vakhrushev
  • S. V. Pavlovich
  • K. N. Yarygin
  • G. T. Sukhikh
Translated from Kletochnye Tekhnologii v Biologii i Meditsine (Cell Technologies in Biology and Medicine)

We studied immunosuppressive properties of skin fibroblasts and mesenchymal stromal cells against NK cells. In vitro experiments showed that mesenchymal stromal cells isolated from human umbilical cord and human skin fibroblasts can considerably attenuate cytotoxic activity of NK cells against Jurkat cells sensitive to NK-mediated lysis. NK cells cultured in lymphocyte population exhibited higher cytotoxic activity than isolated NK cells. Mesenchymal stromal cells or fibroblasts added 1:1 to lymphocyte culture almost completely suppressed NK cell cytotoxicity. This suggests that fibroblast-like cells can suppress not only isolated NK cells, but also NK cells in natural cell microenvironment.

Key Words

mesenchymal stromal cells fibroblasts lymphocytes NK cells immunosuppression 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Abakushina EV, Kuzmina EG, Kovalenko EI. The main characteristics of human natural killer cells. Immunologiya. 2012;33(4):220-224. Russian.Google Scholar
  2. 2.
    Vdovin AS, Lupatov AY, Kholodenko IV, Yarygin KN. Comparison of the efficiency of viral transduction and episomal transfection in human fibroblast reprogramming. Bull. Exp. Biol. Med. 2015;160(1):123-128.CrossRefPubMedGoogle Scholar
  3. 3.
    Lupatov AY, Vdovin AS, Vakhrushev IV, Poltavtseva RA, Yarygin KN. Comparative analysis of the expression of surface markers on fibroblasts and fibroblast-like cells isolated from different human tissues. Bull. Exp. Biol. Med. 2015;158(4):537-543.CrossRefPubMedGoogle Scholar
  4. 4.
    Lupatov AY, Karalkin PA, Suzdal’tseva YG, Burunova VV, Yarygin VN, Yarygin KN. Cytofluorometric analysis of phenotypes of human bone marrow and umbilical fibroblast-like cells. 2006;142(4):521-526.Google Scholar
  5. 5.
    Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 2005;105(4):1815-1822.CrossRefPubMedGoogle Scholar
  6. 6.
    Bartholomew A, Sturgeon C, Siatskas M, Ferrer K, McIntosh K, Patil S, Hardy W, Devine S, Ucker D, Deans R, Moseley A, Hoffman R. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 2002;30(1):42-48.CrossRefPubMedGoogle Scholar
  7. 7.
    Blasi A, Martino C, Balducci L, Saldarelli M, Soleti A, Navone S.E, Canzi L, Cristini S, Invernici G, Parati E.A, Alessandri G. Dermal fibroblasts display similar phenotypic and differentiation capacity to fat-derived mesenchymal stem cells, but differ in anti-inflammatory and angiogenic potential. Vasc. Cell. 2011;3(1):5. doi:  10.1186/2045-824X-3-5.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Chen L, Tredget EE, Wu PY, Wu Y. Paracrine factors of mesenchymal stem cells recruit macrophages and endothelial lineage cells and enhance wound healing. PLoS One. 2008;3(4):e1886.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Chen L, Zhang W, Yue H, Han Q, Chen B, Shi M, Li J, Li B, You S, Shi Y, Zhao R.C. Effects of human mesenchymal stem cells on the differentiation of dendritic cells from CD34+ cells. Stem Cells Dev. 2007;16(5):719-731.CrossRefPubMedGoogle Scholar
  10. 10.
    Chen Y, Perussia B, Campbell KS. Prostaglandin D2 suppresses human NK cell function via signaling through D prostanoid receptor. J. Immunol. 2007;179(5):2766-2773.CrossRefPubMedGoogle Scholar
  11. 11.
    DelaRosa O, Sánchez-Correa B, Morgado S, Ramírez C, del Río B, Menta R, Lombardo E, Tarazona R, Casado JG. Human adipose-derived stem cells impair natural killer cell function and exhibit low susceptibility to natural killer-mediated lysis. Stem Cells Dev. 2011;21(8):1333-1343.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Ghannam S, Pène J, Moquet-Torcy G, Jorgensen C, Yssel H. Mesenchymal stem cells inhibit human Th17 cell differentia-tion and function and induce a T regulatory cell phenotype. J. Immunol. 2010;185(1):302-312.CrossRefPubMedGoogle Scholar
  13. 13.
    Götherström C, Lundqvist A, Duprez IR, Childs R, Berg L, le Blanc K. Fetal and adult multipotent mesenchymal stromal cells are killed by different pathways. Cytotherapy. 2011;13(3):269-278.CrossRefPubMedGoogle Scholar
  14. 14.
    Jorgensen C, Djouad F, Apparailly F, Noël D. Engineering mesenchymal stem cells for immunotherapy. Gene Ther. 2003;10(10):928-931.CrossRefPubMedGoogle Scholar
  15. 15.
    Krampera M, Cosmi L, Angeli R, Pasini A, Liotta F, Andreini A, Santarlasci V, Mazzinghi B, Pizzolo G, Vinante F, Romagnani P, Maggi E, Romagnani S, Annunziato F. Role for interferon-gamma in the immunomodulatory activity of human bone marrow mesenchymal stem cells. Stem Cells. 2006;24(2):386-398.CrossRefPubMedGoogle Scholar
  16. 16.
    Le Blanc K. Immunomodulatory effects of fetal and adult mesenchymal stem cells. Cytotherapy 2003;5(6):485-489.CrossRefPubMedGoogle Scholar
  17. 17.
    Poggi A, Prevosto C, Massaro A.M, Negrini S, Urbani S, Pierri I, Saccardi R, Gobbi M, Zocchi M.R. Interaction between human NK cells and bone marrow stromal cells induces NK cell triggering: role of NKp30 and NKG2D receptors. J. Immunol. 2005;175(10):6352-6360.CrossRefPubMedGoogle Scholar
  18. 18.
    Rasmusson I, Le Blanc K, Sundberg B, Ringdén O. Mesenchymal stem cells stimulate antibody secretion in human B cells. Scand. J. Immunol. 2007;65(4):336-343.CrossRefPubMedGoogle Scholar
  19. 19.
    Rasmusson I, Uhlin M, Le Blanc K, Levitsky V. Mesenchymal stem cells fail to trigger effector functions of cytotoxic T lymphocytes. J. Leukoc. Biol. 2007;82(4):887-893.CrossRefPubMedGoogle Scholar
  20. 20.
    Ryan JM, Barry F, Murphy JM, Mahon BP. Interferon-gamma does not break, but promotes the immunosuppressive capacity of adult human mesenchymal stem cells. Clin. Exp. Immunol. 2007;149(2):353-363.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells. 2006;24(1):74-85.CrossRefPubMedGoogle Scholar
  22. 22.
    Spaggiari GM, Abdelrazik H, Becchetti F, Moretta L. MSCs inhibit monocyte-derived DC maturation and function by selectively interfering with the generation of immature DCs: central role of MSC-derived prostaglandin E2. Blood. 2009;113(26):6576-6583.CrossRefPubMedGoogle Scholar
  23. 23.
    Spaggiari GM, Capobianco A, Abdelrazik H, Becchetti F, Mingari MC, Moretta L. Mesenchymal stem cells inhibit natural killer-cell proliferation, cytotoxicity, and cytokine production: role of indoleamine 2,3-dioxygenase and prostaglandin E2. Blood. 2008;111(3):1327-1333.CrossRefPubMedGoogle Scholar
  24. 24.
    Spaggiari GM, Capobianco A, Becchetti S, Mingari MC, Moretta L. Mesenchymal stem cell-natural killer cell interactions: evidence that activated NK cells are capable of killing MSCs, whereas MSCs can inhibit IL-2-induced NK cell proliferation. Blood. 2006;107(4):1484-1490.CrossRefPubMedGoogle Scholar
  25. 25.
    Thomas H, Jäger M, Mauel K, Brandau S, Lask S, Flohé S.B. Interaction with mesenchymal stem cells provokes natural killer cells for enhanced IL-12/IL-18-induced interferon-gamma secretion. Mediators Inflamm. 2014;2014. ID 143463. doi:  10.1155/2014/143463. http://dx.doi.org/ 10.1155/2014/143463.
  26. 26.
    Tu Z, Li Q, Bu H, Lin F. Mesenchymal stem cells inhibit complement activation by secreting factor H. Stem Cells Dev. 2010;19(11):1803-1809.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Vallera DA, Felices M, McElmurry R, McCullar V, Zhou X, Schmohl JU, Zhang B, Lenvik AJ, Panoskaltsis-Mortari A, Verneris MR, Tolar J, Cooley S, Weisdorf DJ, Blazar BR, Miller JS. IL15 trispecific killer engagers (TriKE) make natural killer cells specific to CD33+ targets while also inducing persistence, in vivo expansion, and enhanced function. Clin. Cancer Res. 2016;22(14):3440-3450.CrossRefPubMedGoogle Scholar
  28. 28.
    Zamai L, Ahmad M, Bennett IM, Azzoni L, Alnemri ES, Perussia B. Natural killer (NK) cell-mediated cytotoxicity: differential use of TRAIL and Fas ligand by immature and mature primary human NK cells. J. Exp. Med. 1998;188(12):2375-2380.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • A. Yu. Lupatov
    • 1
    • 2
  • Ya. S. Kim
    • 1
    • 2
  • O. A. Bystrykh
    • 2
  • I. V. Vakhrushev
    • 1
    • 2
  • S. V. Pavlovich
    • 2
  • K. N. Yarygin
    • 1
    • 2
  • G. T. Sukhikh
    • 1
    • 2
  1. 1.V. N. Orekhovich Research Institute of Biomedical ChemistryMoscowRussia
  2. 2.V. I. Kulakov Research Center of Obstetrics, Gynecology, and PerinatologyMinistry of Health of the Russian FederationMoscowRussia

Personalised recommendations